Advertisement
St. Jude Medical
Subscribe to St. Jude Medical
View Sample

FREE Email Newsletter

St. Jude Medical Reports Positive Clinical Outcomes from Portico Heart Valve Study

October 28, 2013 9:37 pm | by Business Wire | News | Comments

St. Jude Medical, Inc., a global medical device company, today announced positive results for the 23 and 25 mm Portico Transcatheter Aortic Heart Valves in the Portico Transfemoral CE Mark Trial. Patients enrolled in the study experienced a...

New Data from St. Jude Medical Study of EnligHTN Renal Denervation System Presented

October 28, 2013 9:22 pm | by Business Wire | News | Comments

St. Jude Medical, Inc., a global medical device company, today announced new results from the EnligHTN I study, confirming safe, rapid and sustained reduction in blood pressure measurements a year and a half post-procedure. Data presented at...

TCT 2013: Renal denervation does everything

October 28, 2013 4:35 pm | by Mass Device | News | Comments

Renal denervation may have lost some of its hype over the course of the last year, but researchers are still findings new ways to utilize the technology to target new diseases. Technologies such as Medtronic's Symplicity and St. Jude Medical's...

Advertisement

St. Jude Medical seeks to toss shareholders class action

October 17, 2013 3:59 pm | by Mass Device | News | Comments

St. Jude Medical wants a federal judge in Minnesota to toss a class action lawsuit filed by shareholders after the medical device company's stock took a dive in 2009 when it reduced its guidance. The lawsuit, filed in March 2010, alleges that St. Jude...

Rare Serious Erosion Events Associated with St. Jude Amplatzer Atrial Septal Occluder (ASO)

October 17, 2013 12:00 am | by U.S. Food & Drug Administration | News | Comments

The St. Jude Amplatzer Atrial Septal Occluder is a cardiac implant device used in children and adults to treat an abnormal hole between the upper left and right chambers of the heart, known as an atrial septal defect. The metal device is put...

St. Jude Gets EU Approval for Wireless Pacemaker

October 14, 2013 12:02 am | by The Associated Press | News | Comments

St. Jude Medical says it will announce Monday that it received European approval to market the first pacemaker that does not require wires to attach to the heart. The first-of-a-kind device was developed by California-based startup, Nanostim...

St. Jude CEO Starks snarks rivals' 'lack of imagination'

October 11, 2013 2:39 pm | by Mass Device | News | Comments

St. Jude Medical (NYSE:STJ) CEO Daniel Starks has his own key to success, and it doesn't jibe well with some of his rivals, who he left unnamed in his criticism. Starks told an audience at the Minnesota Venture Finance Conference this week...

Appeals court reverses St. Jude Medical win over Access Closure

September 12, 2013 2:10 pm | by Mass Device | News | Comments

A federal appeals court overturned a portion of a legal win for St. Jude Medical yesterday, ruling that a lower court erred in invoking the "safe harbor" provision against double-patenting claims in a patent infringement lawsuit against Access Closure Inc.

Advertisement

St. Jude’s New Renal Denervation System Reduces Total Ablation Time by More Than 80%

August 29, 2013 10:51 am | by Business Wire | News | Comments

St. Jude Medical, Inc., a global medical device company, today announced the CE Mark approval of its next-generation EnligHTN Renal Denervation System for treating patients with drug-resistant, uncontrolled hypertension. The system features an advanced generator that delivers simultaneous ablations via a multi-electrode catheter...

GPOs: Medtronic, St. Jude, Boston Scientific land new deals from Premier

August 13, 2013 12:27 pm | by Mass Device | News | Comments

Premier Healthcare Alliance awarded several new contracts for drug-eluting stents, traditional stents and other intervention products to 8 heavy hitters in the cardiology space. Abbott, Boston Scientific, and Medtronic all landed supplier deals for drug-eluting and traditional stents.

St. Jude Medical Launches Wireless MRI-Conditional Pacemaker in Japan

June 27, 2013 8:01 am | by Business Wire | News | Comments

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) and launch of the Accent MRI ™ Pacemaker and the Tendril MRI ™ lead.   

St. Jude Medical Receives CE Mark Approval of MultiPoint Pacing CRT-D

June 24, 2013 8:00 am | by Business Wire | News | Comments

St. Jude Medical, Inc., a global medical device company, today announced CE Mark approval of its next-generation quadripolar device, the Quadra Assura MP ™ cardiac resynchronization therapy defibrillator (CRT-D). Built upon the company’s first-to-market Quadripolar Pacing System, the Quadra Assura MP CRT-D features MultiPoint ™ Pacing (MPP) technology that enables physicians to pace multiple locations on the left side of the heart.

High-Voltage Devices from St. Jude Medical Get FDA Approval

June 18, 2013 1:46 pm | by St. Jude Medical | News | Comments

St. Jude Medical (NYSE:STJ) has announced U.S. Food and Drug Administration (FDA) approval of its next-generation Ellipse and SJM Assura portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). The new devices are designed to lower the risk of lead abrasion and to ensure high-voltage therapy delivery.

Advertisement

Approval Of Boston Scientific's Watchman Device Will Support Rapid Growth In The Global Heart Defect Closure Device Market

June 12, 2013 8:00 am | by The Associated Press | News | Comments

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the anticipated Food and Drug Administration (FDA) approval of Boston Scientific's WATCHMAN device will drive rapid growth in the market for global heart defect closure devices. ...

St. Jude Medical Announces FDA Approval of High-Voltage Devices with New Safety Features

June 11, 2013 4:05 pm | by Business Wire | News | Comments

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval of its next-generation Ellipse™ and SJM Assura™ portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). The new devices are designed to lower the risk of lead abrasion and to ensure high-voltage therapy delivery.

St. Jude Medical Signs Equity Investment and Option to Purchase Agreement with Spinal Modulation

June 7, 2013 11:01 am | by Business Wire | News | Comments

St. Jude Medical, Inc., a global medical device company, and privately-held Spinal Modulation, Inc., today announced that they have entered into a series of agreements under which St. Jude Medical made a $40 million equity investment in Spinal Modulation, a company that has developed an innovative neuromodulation therapy that provides a new pain management option for patients with chronic, intractable pain.

St. Jude Medical Initiates First US Clinical Study of the EnligHTN Renal Denervation System for Drug-Resistant High Blood Pressure

June 4, 2013 8:00 am | by Business Wire | News | Comments

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval to begin the EnligHTN IV Renal Denervation Study, the first U.S. trial using the EnligHTN ™ Multi-Electrode Renal Denervation System to treat patients with drug-resistant high blood pressure.

One Year Data from St. Jude Medical Study Demonstrates Safe, Rapid and Sustained Blood Pressure Reduction with EnligHTN Renal Denervation Technology

May 23, 2013 4:15 am | by The Associated Press | News | Comments

ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May 23, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that the company’s EnligHTN ™ Multi-Electrode Renal Denervation System provides a safe, rapid and sustained reduction in blood pressure measurements after...

St. Jude Medical EnligHTNment Study Highlighted at EuroPCR During Trials That May Change Clinical Practice Session

May 21, 2013 9:52 am | by The Associated Press | News | Comments

ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May 21, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the start of its landmark EnligHTNment clinical study. This is the largest randomized, prospective trial to determine whether renal denervation and...

St. Jude Medical Announces First Patient Enrollment in EnligHTN III Renal Denervation Study of Next-Generation EnligHTN System

May 14, 2013 8:00 am | by The Associated Press | News | Comments

ST. PAUL, Minn.--(BUSINESS WIRE)--May 14, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced enrollment of the first patient in the EnligHTN III trial. This study will evaluate the safety and performance of the new second-generation EnligHTN ™ Renal...

St. Jude Medical Announces Results from Independent Analysis of Optim-Insulated Defibrillation Leads in Late-Breaking Clinical Trial Session at Heart Rhythm 2013

May 9, 2013 1:55 pm | by The Associated Press | News | Comments

ST. PAUL, Minn.--(BUSINESS WIRE)--May 9, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the Population Health Research Institute (PHRI), an academic health science research institute, has conducted a further independent analysis of data received from...

St. Jude Medical Announces CE Mark Approval of Next-Generation Ellipse and SJM Assura High Voltage Devices

May 8, 2013 8:00 am | by The Associated Press | News | Comments

ST. PAUL, Minn.--(BUSINESS WIRE)--May 8, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced CE Mark approval of its next-generation Ellipse™ and SJM Assura™ portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy...

St. Jude Medical Enrolls First Patient in Next-Generation Quadra Study

May 3, 2013 9:46 am | by Business Wire | News | Comments

St. Jude Medical, a global medical device company, today announced first enrollment of its MultiPoint Pacing clinical study to build upon its first- to-market Quadripolar Pacing System. Patients will be implanted with the Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) and Quartet lead to assess pacing in multiple locations in the heart.

Patients Slap St. Jude Medical with Lawsuits over Recalled Riata Heart Wires

April 5, 2013 2:27 pm | by Mass Device | News | Comments

St. Jude Medical was slapped with multiple lawsuits in California courts yesterday over its recalled Riata defibrillator lead, alleging that the heart wires were defective and led to injuries or death for more than 30 patients. The lawsuits generally accuse St. Jude of violating both state and federal requirements for reporting issues with medical devices...

Will Another Durata Failure Report Drag St. Jude Down?

March 28, 2013 1:31 pm | by Mass Device | News | Comments

Wall Street didn't move much on news of another insulation-related failure in St. Jude Medical's next-generation Durata defibrillator leads this week. The case report included a detailed analysis of an incident in which a Durata lead failed due to inside-out abrasion...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading